Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Janssen Vaccines Corp., A Johnson & Johnson Company
WARNING LETTER
•Janssen Vaccines Corp., A Johnson & Johnson Company•November 19, 2024

Janssen Vaccines Corp., A Johnson & Johnson Company – FDA Warning Letter, Nov 19, 2024

Record Details

The FDA issued a Warning Letter to Janssen Vaccines Corp., A Johnson & Johnson Company, following an inspection conducted from November 11 to 19, 2024. The letter identified significant violations of Current Good Manufacturing Practice (CGMP) regulations, outlined in 21 CFR parts 210 and 211, rendering the company"s drug product adulterated under the Federal Food, Drug, and Cosmetic Act.

The primary violation involved the company"s failure to thoroughly investigate recurring complaints received between November 2023 and November 2024, specifically concerning stopper issues with an injectable drug. Investigations were deemed inadequate, lacking comprehensive assessments of human use, manufacturing, and stability factors, and failing to consistently collect relevant samples. The FDA stated that revisions to instructions could not substitute for ensuring product quality.

Furthermore, the quality unit failed to consistently uphold its responsibility to ensure CGMP compliance and product quality. This was evidenced by an insufficient escalation and action on multiple stopper-related complaints, leading to a failure in consistently following procedures for timely regulatory notification of product quality defects, such as Biological Product Deviation Reports.

To address these issues, the FDA requires Janssen to provide a comprehensive assessment and remediation plan for its overall system for investigating deviations, discrepancies, and complaints. This includes a detailed plan to further assess the recurring stopper issues, involving comparative analyses of sterilization and container closure system assembly processes, and human use factors. A retrospective review of all stopper complaints from the last three years and an independent review of the company"s complaint handling program are also mandated.

Company
Janssen Vaccines Corp., A Johnson & Johnson Company
Inspection date
November 19, 2024
Product type
Other
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 8e402d70-0745-4653-ab5c-c9e641dd0991

Violation Codes9
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 U.S.C. 351(a)(2)(B)21 CFR 211.19221 CFR 211.2221 U.S.C. 356C(b)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Janssen Vaccines Corp., A Johnson & Johnson Company
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.